As a result, the FDA accelerated the approval of DS-8201a for unresectable or metastatic HER2-positive NSCLC that had received systemic therapy this past August, making it the first HER2-targeted therapy for lung cancer. This evidence concerns the gene ERBB2 and lung cancer.